ArticleCell reports2019
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 143 citations in OpenAlex.
- ZO-2 blocks the localization of PGAM5 protein to the mitochondrial membrane and suppresses pancreatic cancer malignancy through metabolic reprogramming.Genes & diseases · 2027Article
- Remodeling of mitochondrial dynamics by metabolic pathways couples to oncogenic growth inScience advances · 2026Article
- Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells.British journal of cancer · 2026Article
- Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.Cell death & disease · 2026Article
- ATR kinase inhibitors induce mitochondrial fission in CD8bioRxiv : the preprint server for biology · 2026Article
- Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells.bioRxiv : the preprint server for biology · 2026Article
- Article
- Implications of ferritinophagy in cardiovascular diseases and its pharmacological modulation: underlying mechanisms and clinical translation strategies.Cellular & molecular biology letters · 2026Review
- Imbalances of mitochondrial dynamics in solid tumors.Oncogenesis · 2026Review
- Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies.Cell death discovery · 2026Review
- Context-dependent inhibitory roles of RhoA in 3D invasive cell migration within the extracellular matrix.Cell reports · 2025Article
- Targeting mitochondrial structure and dynamics for therapeutic intervention in cancer.PLoS biology · 2025Article
- Review
- Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Mitochondrial Dynamics Through the Lens of Nonlinear Chemical Oscillations: A Theoretical Exploration Inspired by the Belousov-Zhabotinsky Reaction.bioRxiv : the preprint server for biology · 2025Article
- Shape Matters: The Utility and Analysis of Altered Yeast Mitochondrial Morphology in Health, Disease, and Biotechnology.International journal of molecular sciences · 2025Review
- Subcellular Organelle Targeting as a Novel Approach to Combat Tumor Metastasis.Pharmaceutics · 2025Review
- Metabolic plasticity in pancreatic cancer: The mitochondrial connection.Molecular metabolism · 2025Review
- The interconnective role of the UPS and autophagy in the quality control of cancer mitochondria.Cellular and molecular life sciences : CMLS · 2025Review
- Mechanistic insights into promotion of non-small cell lung cancer by BAG5 using integrative multi-omics approaches.Frontiers in immunology · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Sarbajeet NagdasDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Jennifer A KashatusDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Aldo NascimentoDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Syed S HussainDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Riley E TrainorDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Sarah R PollockDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Sara J AdairDepartment of Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA.
Alex D MichaelsDepartment of Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA.
Hiromi SesakiDepartment of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Edward B StelowDepartment of Pathology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Todd W BauerDepartment of Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA.
David F KashatusDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA. Electronic address: kashatus@virginia.edu.
University of Virginia Health System · USJohns Hopkins University · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1MCancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4MTRAINING IN CELL AND MOLECULAR BIOLOGYT32GM008136 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI STUKENBERG, P. TODD · 1985 to 2020
$8.5MTraining in Cell and Molecular BiologyT32GM139787 · NIGMS · UNIVERSITY OF VIRGINIA · PI Bryce Paschal · 2021 to 2026
$2.5MExploring the Role of Mitochondrial Fission in Pancreatic TumorigenesisR01CA200755 · NCI · UNIVERSITY OF VIRGINIA · PI KASHATUS, DAVID FRANCIS · 2016 to 2020
$2.2MMitochondrial Quality Control by Drp1R01GM123266 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI SESAKI, HIROMI · 2018 to 2021
$1.4MRegulation of Mitochondrial Division by Phosphatidic AcidR01GM130695 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI SESAKI, HIROMI · 2019 to 2021
$933kNCI NIH HHS L30 CA124093NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA200755NCI NIH HHS T32 CA009109NIGMS NIH HHS R01 GM123266NIGMS NIH HHS R01 GM130695NIGMS NIH HHS T32 GM007267NIGMS NIH HHS T32 GM008136NIGMS NIH HHS T32 GM139787
Abstract
Mitochondria undergo fission and fusion to maintain homeostasis, and tumors exhibit the dysregulation of mitochondrial dynamics. We recently demonstrated that ectopic HRas
Indexed as
AnimalsApoptosisCell ProliferationDynaminsGene Expression Regulation, NeoplasticGlycolysisHumansMiceMice, KnockoutMitochondriaMitochondrial DynamicsPancreatic NeoplasmsPhosphorylationProto-Oncogene Proteins p21(ras)Tumor Cells, CulturedXenograft Model Antitumor AssaysDNM1L protein, humanDnm1l protein, mouseDynaminsKRAS protein, humanProto-Oncogene Proteins p21(ras)Drp1KRasmetabolismmitochondriapancreatic cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.